ARHGAP10 Activators
ARHGAP10 Activators encompass a group of compounds that indirectly enhance the function of ARHGAP10, primarily through the modulation of Rho family GTPase signaling pathways. The compounds listed do not activate ARHGAP10 directly; rather, they influence the signaling landscape in which ARHGAP10 operates, often through inhibitory actions on Rho GTPase family members or their associated kinases and exchange factors. This indirect activation can result from the inhibition of downstream effectors such as ROCK with compounds like Y-27632 and Fasudil or upstream regulatory components like GEFs with molecules such as NSC 23766 and CID-1067700. The overall effect of these chemicals is to shift the balance of GTPase signaling in the cell, leading to a compensatory increase in ARHGAP10 activity to maintain cellular equilibrium.
The chemical actions serve to create a regulatory environment that supports the activity of ARHGAP10. For example, the inhibition of prenylation of RhoA by statins like Lovastatin might necessitate an increase in ARHGAP10 activity to regulate the unprenylated RhoA. Similarly, the inhibition of other Rho family GTPases, such as Cdc42 by ML141 or Rac1 by EHop-016, may also prompt an upregulation of ARHGAP10.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 is a selective inhibitor of the transcription factor SRF (serum response factor), which is modulated by RhoA signaling. Inhibition of SRF can lead to alterations in cytoskeletal dynamics and potential compensatory increases in ARHGAP10 activity. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID-1067700 competitively inhibits GEFs for Rho GTPases, which can lead to a compensatory increase in ARHGAP10 activity to balance Rho GTPase signaling. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Rhosin directly inhibits RhoA by preventing its activation by GEFs. This may trigger compensatory mechanisms within the cell that lead to increased ARHGAP10 activity in order to maintain RhoA signaling control. | ||||||
ITX 3 | 347323-96-0 | sc-295214 sc-295214A | 10 mg 50 mg | $145.00 $615.00 | ||
ITX3 is a selective inhibitor of Trio, a GEF for Rho GTPases including Rac1 and RhoG, which might cause an indirect upregulation of ARHGAP10 activity as a feedback mechanism. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
CASIN inhibits the activation of Cdc42, potentially leading to a regulatory feedback loop that enhances ARHGAP10 activity to maintain equilibrium in Rho GTPase signaling pathways. | ||||||
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $80.00 | ||
EHop-016 inhibits Vav2, a GEF for Rac1, which could potentially lead to increased ARHGAP10 activity in response to alterations in Rho family GTPase dynamics. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 is a Cdc42 GTPase inhibitor that disrupts the interaction between Cdc42 and its GEFs, potentially leading to a compensatory increase in ARHGAP10 activity as part of the cell's response to altered GTPase signaling. | ||||||